significantepidemiology
Global FMF registry reveals declining amyloidosis incidence with early colchicine
Familial Mediterranean Fever →Summary
Data from the international Eurofever/PRINTO registry covering over 2,800 FMF patients showed that AA amyloidosis incidence has dropped from 15-20% historically to under 2% in patients who start colchicine early. This reinforces the importance of prompt diagnosis and lifelong colchicine adherence.
Related treatments
More from Familial Mediterranean Fever
significantTreatment update
JAK inhibitors (tofacitinib) emerging as potential third-line therapy
significantTreatment update
IL-1 blockade established as standard second-line therapy for colchicine-resistant FMF
significantTreatment update
EULAR/PReS 2024 updated management recommendations published
significantNew research
Colchicine resistance mechanisms linked to pyrin inflammasome microtubule independence
ID: familial-mediterranean-fever-update-8Type: epidemiologyImpact: significant